DDrare: Database of Drug Development for Rare Diseases

269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群
［臨床試験数：20，薬物数：26（DrugBank：10），標的遺伝子数：12，標的パスウェイ数：90］

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = APD334; Adalimumab; CICLOSPORIN; Canakinumab; Ciclosporin; Cosentyx; Cosentyx®; EU/1/14/980/002; EU/1/14/980/003; Gelatin; Gevokizumab; Gevokizumab open-label; Humira; IFX-1; Infliximab; Ixekizumab; Neoral Oral Solution; Neoral soft gelatin capsules; PREDNISOLONE; Prednisolone; Secukinumab; Secukinumab 150 mg (2 injections per dose; Stelara; USTEKINUMAB; Ustekinumab; Xilonix

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03311464 (ClinicalTrials.gov)	October 27, 2017	12/10/2017	A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan	A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan	Pyoderma Gangrenosum	Drug: adalimumab	AbbVie	NULL	Completed	18 Years	N/A	All	22	Phase 3	Japan
2	NCT00730717 (ClinicalTrials.gov)	May 2009	4/8/2008	Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum	Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: Humira	Wright State University	Stanford University;Wake Forest School of Medicine	Withdrawn	18 Years	N/A	Both	20	Phase 2	United States
3	NCT00690846 (ClinicalTrials.gov)	July 2007	2/6/2008	Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum	A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)	Pyoderma Gangrenosum	Drug: adalimumab	Wake Forest University Health Sciences	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03311464
(ClinicalTrials.gov)

October 27, 2017

12/10/2017

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan

Pyoderma Gangrenosum

Drug: adalimumab

AbbVie

NULL

Completed

18 Years

N/A

All

Phase 3

Japan

NCT00730717
(ClinicalTrials.gov)

May 2009

4/8/2008

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Pyoderma Gangrenosum

Drug: Humira

Wright State University

Stanford University;Wake Forest School of Medicine

Withdrawn

18 Years

N/A

Both

Phase 2

United States

NCT00690846
(ClinicalTrials.gov)

July 2007

2/6/2008

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37)

Pyoderma Gangrenosum

Drug: adalimumab

Wake Forest University Health Sciences

NULL

Withdrawn

18 Years

N/A

All

Phase 2

United States